Stock LIPO LIPELLA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Lipella Pharmaceuticals Inc.

Equities

LIPO

US53630L1008

Market Closed - Nasdaq
Other stock markets
 21:30:01 20/05/2024 BST 		5-day change 1st Jan Change
0.755 USD +0.53% Intraday chart for Lipella Pharmaceuticals Inc. +3.04% -25.98%
05-09 Lipella Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-17 Lipella Pharmaceuticals Inc. Appoints Jason Hafron and Pradeep Tyagi to Scientific Advisory Board CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lipella Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
CI
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Lipella Pharmaceuticals Inc. Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus
CI
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Lipella Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Lipella Pharmaceuticals Enters Manufacturing Deal With Cook MyoSite for Potential Treatment of Hemorrhagic Cystitis
MT
Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite
CI
Lipella Pharmaceuticals Doses First Patient in Bladder MRI Contrast Agent Trial
MT
Lipella Pharmaceuticals Doses First Patient in Human Study of Innovative Contrast Agent
CI
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Lipella Pharmaceuticals Inc. Successfully Completes Phase 2A Clinical Trial; Announces Late Breaking Presentation At the Annual Meeting of the American Urological Association
CI
Lipella Pharmaceuticals Inc. Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10
CI
Lipella Pharmaceuticals Inc. has completed an IPO in the amount of $6.999998 million.
CI
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Lipella Pharmaceuticals Inc. has filed an IPO in the amount of $11.5 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LIPO Stock
  4. News Lipella Pharmaceuticals Inc.
  5. Highlights